Microfluidic Droplet Merging for High-Throughput TCR Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and characterizing neoantigens specific to cancer patients are laborious, time-consuming, and costly, limiting the development of personalized T-cell therapies due to the lack of high-throughput technologies for evaluating patient-specific mutations and determining cognate T-cell receptors.
Innovation Solution
A microfluidic device merges discrete entities containing T-cells and neoantigen-presenting cells to form combined entities, allowing for rapid detection of T-cell activation through cytokine release or granzyme B detection, enabling the identification of polyfunctional T-cells and NK-cells that could be cytotoxic when injected into a subject.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional methods are used to identify and characterize neoantigens, then measurement precision is maintained, but productivity is severely limited and loss of time is excessive
Solution Approach 1:
The patent segments the neoantigen identification process into discrete droplet-based assays, where individual T-cells and neoantigen-presenting cells are isolated in separate droplets. This segmentation enables parallel processing of multiple cell pairs simultaneously, dramatically increasing throughput while reducing the time required for characterization compared to traditional sequential methods.
Solution Approach 2:
The patent changes the physical parameters of the assay system by transitioning from conventional well-based formats to microfluidic droplet formats. This parameter change enables automated high-throughput processing, reduces manual intervention time, and accelerates the overall characterization process while maintaining measurement precision through standardized droplet conditions.
2Productivity
If traditional methods are used for neoantigen screening, then measurement precision is maintained, but productivity remains low and device complexity is avoided
Solution Approach 1:
The microfluidic device is designed with multi-functionality, serving as both the mixing chamber and the screening platform. The same device generates droplets containing T-cells and neoantigen-presenting cells, maintains them during incubation, and enables detection of T-cell activation. This universal design increases screening capacity without proportionally increasing device complexity.
Solution Approach 2:
The patent merges multiple functional steps into a single integrated microfluidic system. Cell mixing, droplet generation, incubation, and detection are combined in one device, eliminating the need for separate equipment for each step. This merging approach dramatically increases productivity while the modular microfluidic design keeps overall system complexity manageable.
3Productivity
If high-throughput methods are implemented, then productivity increases, but device complexity increases and ease of operation decreases
Solution Approach 1:
The microfluidic device is designed to perform automated operations without requiring complex manual intervention. The system self-regulates droplet generation, cell pairing, and incubation conditions through integrated microfluidic control mechanisms. This self-service capability enables high throughput (forming at least one thousand combined discrete entities in about one second) while maintaining ease of operation, as the automation handles the complexity internally.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces the time and cost associated with identifying neoantigen-specific T-cell receptors, facilitating the development of personalized therapies by enabling high-throughput screening and characterization of neoantigen-TCR pairs, potentially leading to more effective and durable immune responses with minimal side effects.
Implementation Method 1
a trapping element in order to generate a combined discrete entity
Data Source
AI summary
The present invention provides compositions, systems, kits, and methods for analyzing the interaction of T-cells and neoantigen presenting cells (and other cells) via discrete entity (e.g., droplet) microfluids. In certain embodiments, a microfluidic device is used to merge a discrete entity containing a T-cell, and a discrete entity containing a neoantigen presenting cell, at a merger region via a trapping element in order to generate a combined discrete entity. In particular embodiments, at least one thousand of such combined discrete entities are formed in about one second. In some embodiments, whether the receptor on the T-cell sufficiently binds the neoantigen to activate the T-Cell is detected (e.g., via detection of cytokine or granzyme B release). In certain embodiments, provided herein are methods for identifying polyfunctional T-cells or NK-cells, as well as methods of screening for such cells that would be cytotoxic if injected into a subject.